Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at First Analysis dropped their Q1 2018 earnings per share (EPS) estimates for Charles River Laboratories International in a report issued on Monday. First Analysis analyst T. Van. Fleet now anticipates that the medical research company will post earnings per share of $1.29 for the quarter, down from their previous forecast of $1.32. First Analysis also issued estimates for Charles River Laboratories International’s Q2 2018 earnings at $1.43 EPS, Q3 2018 earnings at $1.38 EPS and FY2018 earnings at $5.50 EPS.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The company had revenue of $464.23 million for the quarter, compared to the consensus estimate of $458.93 million. During the same period last year, the company posted $1.18 EPS. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year.

CRL has been the topic of a number of other reports. Credit Suisse Group restated a “neutral” rating and issued a $112.00 price target (up from $95.00) on shares of Charles River Laboratories International in a research note on Monday, October 16th. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a research note on Tuesday, October 24th. ValuEngine downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Jefferies Group restated a “buy” rating and issued a $120.00 price target on shares of Charles River Laboratories International in a research note on Tuesday, September 12th. Finally, SunTrust Banks restated a “buy” rating and issued a $113.00 price target on shares of Charles River Laboratories International in a research note on Friday, November 17th. Six research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $110.21.

Charles River Laboratories International (NYSE:CRL) traded down $0.30 on Tuesday, hitting $109.44. 229,300 shares of the stock were exchanged, compared to its average volume of 377,466. Charles River Laboratories International has a one year low of $73.81 and a one year high of $119.05. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. The firm has a market cap of $5,197.45, a P/E ratio of 21.56, a P/E/G ratio of 1.75 and a beta of 0.89.

A number of hedge funds and other institutional investors have recently modified their holdings of CRL. YorkBridge Wealth Partners LLC raised its holdings in Charles River Laboratories International by 445.5% during the 3rd quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock worth $118,000 after purchasing an additional 891 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its holdings in Charles River Laboratories International by 69.0% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after purchasing an additional 548 shares during the last quarter. Advisor Group Inc. raised its holdings in Charles River Laboratories International by 159.4% during the 3rd quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after purchasing an additional 945 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Charles River Laboratories International by 12.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after purchasing an additional 202 shares during the last quarter. Finally, Riverhead Capital Management LLC raised its holdings in Charles River Laboratories International by 14.7% during the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after purchasing an additional 247 shares during the last quarter. Institutional investors and hedge funds own 95.80% of the company’s stock.

In related news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $0.27, for a total value of $270,000.00. Also, Director C Richard Reese sold 10,227 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total transaction of $1,047,244.80. Following the completion of the transaction, the director now owns 51,444 shares of the company’s stock, valued at approximately $5,267,865.60. The disclosure for this sale can be found here. In the last quarter, insiders purchased 10,500 shares of company stock valued at $2,885 and sold 1,056,776 shares valued at $2,011,952. 2.20% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Q1 2018 EPS Estimates for Charles River Laboratories International, Inc. Reduced by Analyst (CRL)” was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/q1-2018-eps-estimates-for-charles-river-laboratories-international-inc-reduced-by-analyst-crl-2/1776512.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.